Primelink BioTherapeutics

Primelink BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation multi-functional biologics for oncology and immune-related diseases. The company leverages its proprietary Prime-Engager platform to engineer bispecific and multi-specific antibodies that enable precise immune cell activation within the tumor microenvironment while minimizing systemic toxicity. Their lead clinical program, PB-722, is a PD-L1/4-1BB bispecific antibody currently undergoing Phase 1 evaluation for advanced solid tumors. Additionally, the company is advancing PB-2301, a GPC3/CD3 T-cell engager designed to treat hepatocellular carcinoma. With a focus on addressing high unmet medical needs in solid tumors, Primelink operates an integrated R&D model with facilities in both China and the United States. The leadership team consists of industry veterans with extensive experience in antibody engineering from major pharmaceutical firms such as AbbVie and Amgen.